Actos® Bladder Cancer Settlement Moving Forward
October 7th, 2015|
Actos® is a drug by Takeda Pharmaceuticals, Inc. used to effectively treat diabetes. Unfortunately, researchers have linked the use of Actos with the development of bladder cancer.
In April, Takeda offered $2.3 billion to settle many of the Actos bladder cancer lawsuits in the wake findings showing a link between the drug and the disease. Now, the settlement is moving forward.
FiercePharma explains that as many as 96 percent of plaintiffs who filed Actos bladder cancer lawsuits agreed to the terms of the settlement after Takeda added another $100,000 to the fund used to compensate the victims.
If the settlement becomes finalized, it will lay to rest seven of the nine Actos bladder cancer lawsuits Takeda is currently facing. A statement from executives at Takeda stated the company hopes the settlement will allow all parties involved to avoid “the uncertainties of complex litigation.”
Despite the settlement, Actos remains on the market and Takeda says they will continue to back the drug in the future.
At Fleschner, Stark, Tanoos & Newlin, we believe in holding drugmakers accountable for the safety of the products they release onto the American market. That’s why our drug injury lawyers are hopeful this settlement can help those who developed bladder cancer as a result of taking Actos get back on their feet.